-
Cyproterone
- indication:For the palliative treatment of patients with advanced prostatic carcinoma.
- pharmacologypharmacology:
- mechanism: The direct antiandrogenic effect of cyproterone is blockage of the binding of dihydrotestosterone to the specific receptors in the prostatic carcinoma cell. In addition, cyproterone exerts a negative feed-back on the hypothalamo-pituitary axis, by inhibiting the secretion of luteinizing hormone resulting in diminished production of testicular testosterone.
- toxicity:
- absorprion: Completely absorbed following oral administration.
- halflife: Elimination Following oral or intramuscular administration, the plasma half-life is 38 and 96 hours, respectively.
- roouteelimination:
- volumedistribution:
- clearance: